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Multiple endocrine neoplasia type 1 (MEN-1) is inherited as
an autosomal dominant disease characterised by hyperplasia
or neoplasia of the parathyroids, anterior pituitary and the
endocrine pancreas (Wermer, 1954). Recently, both para-
thyroid and pancreatic lesions in MEN-1 have been reported
to show allelic loss of heterozygosity on chromosome 11
(Larson et al., 1988; Friedman et al., 1989; Thakker et al.,
1989; Yoshimoto et al., 1989). In the case of the parathyroid,
a similar change was reported with sporadic adenoma (Fried-
man et al., 1989). We believe the present study is the first
report of allelic loss in a sporadic pancreatic endocrine
tumour. The genetic pattern of two pancreatic endocrine
tumours (one a sporadic glucagonoma and the other a
neuroendocrine pancreatic tumour from a patient with
MEN-1) was studied using the INT-2 (SS6) probe which
maps to chromosome 11 band q13 (Casey et al., 1986).
The MEN-1 patient was a 23-year-old female with a strong
family history of MEN-1 involving her father and his 4
siblings, and 4 of the patient's paternal cousins. From the age
of 18 years, she complained of amenorrhea, increased ap-
petite and weight gain. Serum calcium was elevated and
abdominal ultrasound showed a mass 4 cm in diameter in the
head of the pancreas. This pancreatic tumour was treated by
local excision and histology of the tumour including im-
munohistochemical staining, indicated a neuroendocrine tu-
mour of uncertain type. The second patient with a his-
tologically confirmed pancreatic glucagonoma was considered
to be a sporadic case as there was no family history of
endocrine disease and the patient's serum calcium, prolactin
and gastrin were all normal.
Peripheral blood from which high molecular weight DNA
was extracted (Miller et al., 1988) was obtained from both
patients as well as the affected parent (father). A portion of
each tumour was sent for histological examination and the
remainder used for DNA extraction following pulverisation
in liquid nitrogen. DNA was digested with Taq 1 for the
sporadic case and BamHl for the MEN-1 case and separated
through 1.2% or 0.8% agarose gels respectively before trans-
fer to nylon membranes (Southern, 1975). The INT-2 (SS6)
was radiolabelled by random priming (Rigby et al., 1977)
using a32P-dCTP and hybridisation was carried out at 65°C
(Freytag, 1988).
Figure 1 shows that the constitutional DNA from both
patients was heterozygous at the INT-2 (SS6) locus. For the
sporadic case, the two TaqI alleles comprised a 4.2 kb frag-
ment (allele 1) and a 2.3 kb fragment (allele 2) and allele 2
was lost in the tumour. For the MEN-I case, the two
BamHl alleles comprised an 8.4 kb fragment (allele 1), and
two shorter fragments, 5.6 kb and 2.8 kb (allele 2). The two
shorter fragments (allele 2) were lost in the tumour. The
constitutional DNA of the affected parent of the MEN-1
patient was homozygous for the BamHl allele 1.
In this study we have shown that the tumour DNA from
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Figure 1 Autoradiograph of DNA from a sporadic and a fam-
ilial (MEN-1) pancreatic endocrine tumour, and the affected
parent of the MEN-I case (C = constitutional DNA, T = tumour
DNA). In both tumours there is loss of somatic heterozygosity at
the INT-2 locus. The affected parent's constitutional DNA is
shown to be homozygous (1,1).
both a sporadic and a familial (MEN-l) pancreatic tumour
were associated with allelic loss at the same locus (Figure 1).
To the best of our knowledge this is the first report detailing
an allelic loss in a sporadic pancreatic tumour and indicates
the possibility that both sporadic and MEN-I associated
pancreatic tumours share the same final genetic basis. Onco-
genesis in the MEN-1 case resulted when the normal allele
was lost thereby unmasking the mutated allele. Since the
affected father was homozygous (1,1) and the affected daugh-
ter was heterozygous (1,2), allele 2 (i.e. the normal alrele)
must have been inherited from the unaffected mother. The
sporadic pancreatic tumour presumably involved a mutation
and a deletion of the normal allele in a similar manner except
that both these chromosomal alterations occurred in the
somatic cells. These conclusions are consistent with Knud-
son's two-hit theory of carcinogenesis (Knudson et al., 1976)
and are supported by the findings for sporadic and familial
(MEN-l associated) parathyroid tumours which have also
been shown to have allelic loss within chromosome band
11q13 (Friedman et al., 1989; Thakker et al., 1989). It is
possible in MEN-1, however, that the second lesion may not
be at the putative disease locus, a situation analagous to that
found in Wilm's tumour, where there is loss ofheterozygosity
which does not seem to be at the site of the gene which leads
to inherited susceptibility. The loss of somatic heterozygosity
observed in this study also suggests that both the sporadic
and familial pancreatic tumours are monoclonal at the time
of clinical presentation, since allelic loss must be present in
most of the tumour cells to be detected with the present
techniques. The data do not, however, prove monoclonality
in tumour origin.
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